Denali Therapeutics Inc. (DNLI)
Summary
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform
Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease company with FDA approval of AVLAYAH for Hunter syndrome. DNLI's TransportVehicle technology enables delivery of biologics across the blood-brain barrier, providing significant differentiation and commercial potential in neurodegenerative and lysosomal storage diseases. With $1.17 billion in pro-forma liquidity and a focused initial launch, DNLI is positioned for 2.8 years of runway, reducing near-term capital risk.
Denali Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 3.73M | $88.09M | $76.35M | -$11.73M | -13.31% |
 Alexandra Stickelman Root Financial Partners, LLC | 188 | $3,201.09 | $3,859.64 | $658.55 | 20.57% |
| NRG Nemes Rush Group LLC Nemes Rush Group LLC | 700 | $20,657 | $14,357 | -$6,301.33 | -30.5% |
 Lu Chen Altitude Crest Partners Inc. | 209,613 | $4.3M | $4.28M | -$20,961.53 | -0.49% |
 Christopher C. Powers Farther Finance Advisors, LLC | 202 | $3,132.27 | $4,143.02 | $1,010.36 | 32.26% |
Denali Therapeutics Inc. (DNLI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Denali Therapeutics Inc. ever had a stock split?
Denali Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ryan J. Watts CEO | NASDAQ (NGS) Exchange | 24823R105 CUSIP |
| US Country | 443 Employees | - Last Dividend | - Last Split | 8 Dec 2017 IPO Date |
Overview
Denali Therapeutics Inc., a pioneering biopharmaceutical entity, dedicates its efforts to the development of a comprehensive portfolio of product candidates. These are specifically engineered to cross the blood-brain barrier, offering innovative therapies for neurodegenerative diseases and lysosomal storage diseases predominantly within the United States. Initially known as SPR Pharma Inc., Denali underwent a rebranding phase in March 2015, transitioning to its current identity. The foundation of Denali Therapeutics Inc. was laid in 2013, and its operational base is strategically located in South San Francisco, California. In its journey towards medical advancement, Denali Therapeutics maintains collaboration agreements with prominent industry leaders, including Biogen MA Inc., Biogen International GmbH, Genzyme Corporation, Takeda Pharmaceutical Company Limited, F-star entities, and Genentech, Inc., amongst others.
Products and Services
- DNL310 ETV (IDS enzyme replacement therapy) - Engineered for MPS II, this therapy illustrates Denali’s venture into lysosomal storage disorders, highlighting its commitment to addressing complex genetic conditions.
- TAK-594/DNL593 (for Frontotemporal Dementia-Granulin) and DNL126 program (for MPS IIIA) - Both under Phase 1/II, these programs exemplify focused efforts on degenerative and storage diseases, respectively, showcasing Denali’s versatility in tackling neurodegenerative disorders.
- DNL622 for MPS I (Hurler Syndrome) - Focuses on a lysosomal storage disorder, representing Denali's approach to genetic disease treatment through innovative therapeutic modalities.
- BIIB122/DNL151 LRRK2 inhibitor - A program aimed at Parkinson’s disease, it stands out for its brain-penetrant small molecule strategy, reflecting Denali’s groundbreaking attempts to target underlying disease mechanisms.
- SAR443820/DNL788 RIPK1 inhibitor - Geared towards CNS diseases, this inhibitor demonstrates Denali’s exploration into neuroinflammation as a therapeutic target.
- DNL343 eIF2B Activator - Targeting amyotrophic lateral sclerosis, it underscores Denali’s commitment to fatal neurodegenerative diseases by attempting to modify disease progression.
- SAR443122/DNL758 RIPK1 inhibitor - Aimed at peripheral inflammatory diseases, it showcases Denali’s ambition in extending its therapeutic reach beyond the central nervous system.
- Oligonucleotide Transport Vehicle platform & Antibody Transport Vehicle Amyloid beta program - These represent groundbreaking efforts to address diseases through genetic modulation and targeted therapy, underscoring Denali’s commitment to innovation in drug delivery and disease treatment mechanisms.
